JMP reiterates Anadys at market perform

Anadys Pharmaceuticals, Inc. was reiterated at market outperform by JMP Securities analyst Adam Cutler following the company's uneventful second-quarter financial results. The Food and Drug Administration has put an official clinical hold on the ANA975 pending additional analysis of 13-week animal toxicity data, according to the analyst. Even with the crowded hepatitis B marketplace and the demonstrated efficacy of ANA380, the analyst believes Anadys should partner with a company that has an existing antiviral sales and marketing presence. Shares of the San Diego-based biopharmaceutical company were down 53 cents, or 15.73%, at $2.84, on volume of 1,296,986 shares versus the three-month running average of 532,652 shares. (Nasdaq: ANDS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.